探索新应用:重新定位临床上已批准的治疗方法来治疗脑髓母细胞瘤
Arthur Karaulic1, Clémence Fournier1, Gilles Pagès1
1University Côte d'Azur, Institute for Research on Cancer and Ageing of Nice (IRCAN, UMR CNRS 7284/U INSERM 1081), 06100 Nice, France.
Cancers
|November 27, 2025
概括
这项研究揭示了小儿癌症脑髓母细胞瘤对药物标的表达有多样性,影响患者的生存. 研究已批准的氨酸激酶抑制剂和其他药物可能为特定脑髓母细胞瘤亚组提供新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 像脑髓母细胞瘤这样的儿科瘤在向治疗方面没有得到充分的研究.
- 氨酸激酶抑制剂 (TKI),治疗抗体和亡诱导剂已经改变了癌症治疗.
- 了解特定脑髓母细胞瘤遗传亚组中的向表达是药物重新定位的关键.
研究的目的:
- 评估73种潜在药物点在脑髓母细胞瘤中的表达.
- 评估目标表达和患者存活率之间的相关性.
- 确定FDA批准的药物在脑髓母细胞瘤中的潜在重新定位机会.
主要方法:
- 分析了来自763名患者 (R2 Genomics平台) 和828名患者 (TCGA) 的RNA测序数据.
- 对TKI,免疫检查点抑制剂 (ICI) 和亡诱导剂的目标的评估表达.
- 检查了针对瘤发生或治疗耐药性相关的突变基因的治疗方法.
主要成果:
- 某些目标的过度表达与脑髓母细胞瘤患者的整体存活率变化相关.
- 特定的免疫检查点抑制剂在各个子组中表现出差异性影响.
- 治疗血液瘤的药物Venetoclax在脑髓母细胞瘤中显示出潜在的疗效.
结论:
- 脑髓母细胞瘤表现出药物标的亚型特定表达,影响生存.
- 已批准的TKIs,ICIs和亲细胞灭绝药物需要在脑髓母细胞瘤中进行临床研究.
- 针对基因子组量身定制的向疗法可以改善结果.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K